Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
about
Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefitStatins in cardiometabolic disease: what makes pitavastatin different?Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive?Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International StudyDoes metformin increase paraoxonase activity in patients with the metabolic syndrome? Additional data from the MEFISTO studyNon-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adultsAn essential role for diet in exercise-mediated protection against dyslipidemia, inflammation and atherosclerosis in ApoE⁻/⁻ mice.Antihyperlipidemic effect of peucedanum pastinacifolium extract in streptozotocin-induced diabetic rats.Lipid accumulation product and 25-OH-vitamin D deficiency in type 2 diabetesPlasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study.Treatment of dyslipidemia in patients with type 2 diabetes.Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentEffects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis.Histamine blood concentration in ischemic heart disease patients.Relationship between the estimates of desaturase activities and cardiometabolic phenotypes in Koreans.Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parametersAssociations of Circulating Oxidized LDL and Conventional Biomarkers of Cardiovascular Disease in a Cross-Sectional Study of the Navajo Population.Structural stability and functional remodeling of high-density lipoproteins.The efficacy and safety of Simvastatin in the treatment of lipid abnormalities in diabetes mellitus.Low HDL cholesterol, smoking and IL-13 R130Q polymorphism are associated with myocardial infarction in Greek Cypriot males. A pilot study.Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery diseCharacterization of lipid parameters in diabetes mellitus--a Nigerian report.Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.Sage tea drinking improves lipid profile and antioxidant defences in humans.TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity.Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment.Overweight adolescents with type 2 diabetes have significantly higher lipoprotein abnormalities than those with type 1 diabetesVisceral adiposity as a target for the management of the metabolic syndrome.α-Lipoic acid as a triglyceride-lowering nutraceutical.Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease.Antihyperlipidemic Activity of the Ethyl-acetate Fraction of Stereospermum Suaveolens in Streptozotocin-induced Diabetic Rats.Effects of oxidation on structural stability and remodeling of human very low density lipoprotein.IRS1, TCF7L2, ADRB1, PPARG, and HHEX polymorphisms associated with atherogenic risk in Mexican population.Glycoxidative stress-induced damage on lipid profile in a fructose-enriched diet model of insulin resistance in rats.Atherogenic lipoprotein parameters in patients with aggressive periodontitis.Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.Grape seed proanthocyanidins correct dyslipidemia associated with a high-fat diet in rats and repress genes controlling lipogenesis and VLDL assembling in liver.The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study.
P2860
Q24650533-3DDBD139-878F-402A-A4BF-71CAFB380DAEQ27010638-35B7BFB8-1F1D-465F-90A0-AC668161D1FBQ28072462-0B6295BB-77EB-4989-AF30-8F9B487F9C73Q28222549-307A4ABD-447B-4E60-9ABA-09AC0438C48FQ33630826-ACFC177F-8BA6-4534-94FD-1FAE88FA516AQ33713488-D748899A-3E6C-4898-8093-41020FC02C2BQ33776151-D41F6147-3926-447D-8AA0-A15C444736D0Q33831999-EF554650-4862-426B-BE4D-9F10AFC05D25Q33967809-EE5B9997-FF60-46FD-B798-D82DA09D3FD8Q34159247-582C7C7B-9B3C-4FC6-B5C0-5E7676A07BEDQ34347027-8B39B87A-E1F9-494A-AB0D-7707E78609C2Q34499472-0207D3DD-1E79-447A-BDB6-96C10A521207Q34627551-60C8CA3A-6293-4F66-AE24-4B74B7CE18E1Q35029623-9483EDAA-5322-4AAD-89AE-2EE815A928D3Q35043813-603E33BC-650D-4532-870C-8CB7793D23B2Q35043956-23EC21AF-3C62-463A-A737-548ABAFA2F30Q35209634-D59DD9F5-BDB0-4F96-A4D8-7DB3A9261AD3Q35440499-55FEB2BC-BD7C-480B-A47D-7300AA788F52Q35944789-D198A3FC-34F7-406B-820B-27237874FDB7Q36031087-460BF9EB-02A4-42A6-90EA-68D9D0EBB98DQ36862146-F77DD7CA-DA6B-4FA8-A37C-CE1957931861Q36944143-E70D4517-B88C-433A-B4B2-593010CC1431Q37211911-E1082B81-98A1-4369-A152-A8917CD1E735Q37325531-8122684D-07E3-4C36-BD46-3172DA0A0CE3Q37376937-0A1D6338-E3B1-42A9-AFE8-856DAB498E23Q37403039-9352B492-D8AF-4639-BB1E-D92862CF7C6FQ37414989-CCC0DF7F-73A8-4463-B457-149EC7FBA292Q37439260-6167890B-2243-4A9F-BC17-CD9E7AB092CAQ37730348-EC41A541-B42E-43F6-AB93-34B5760378C0Q37879666-43158EC0-2E3E-4740-89F4-69683A96C4B2Q38559352-ADE0A32E-42BF-402C-91E2-2FAA90AAE908Q38817895-2E1920A0-9FD0-48EF-99DB-8119C831DDA0Q41205256-C65A2B95-C9A1-4321-822E-9E5E14E05C60Q41724190-5C046DC9-3980-41AD-BD38-075BA943D5B7Q41851616-FAFFC9D7-B558-4DA8-A7EC-8DB606BDC5F7Q43191219-C6A4D95E-A8DA-45ED-91DC-BB95DCCD5CF1Q43519734-E1CC8DCC-6D30-4E82-8BAF-D7F6883884B8Q44936296-807EC31F-AD70-4E30-9BFD-7D785D1EAC48Q45937715-97F86789-E634-4AF9-AE74-81F721258F0BQ46011354-428424D6-5550-4FAD-A8B3-CA40B5392B28
P2860
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Beyond low-density lipoprotein ...... us and the metabolic syndrome.
@ast
Beyond low-density lipoprotein ...... us and the metabolic syndrome.
@en
type
label
Beyond low-density lipoprotein ...... us and the metabolic syndrome.
@ast
Beyond low-density lipoprotein ...... us and the metabolic syndrome.
@en
prefLabel
Beyond low-density lipoprotein ...... us and the metabolic syndrome.
@ast
Beyond low-density lipoprotein ...... us and the metabolic syndrome.
@en
P921
P1476
Beyond low-density lipoprotein ...... us and the metabolic syndrome.
@en
P2093
Richard W Nesto
P304
P356
10.2165/00129784-200505060-00005
P577
2005-01-01T00:00:00Z
P6179
1050447907